Papillary Thyroid Cancer in Childhood and Adolescence with Specific Consideration of Patients After Radiation Exposure by Yuri Demidchik et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Papillary Thyroid Cancer in Childhood and 
Adolescence with Specific Consideration  
of Patients After Radiation Exposure 
Yuri Demidchik1, Mikhail Fridman1, Kurt Werner Schmid3,  
Christoph Reiners2, Johannes Biko2 and Svetlana Mankovskaya1  
1Belarusian Medical Academy for Postgraduate Education,  
2Institute of Pathology and Neuropathology, University Hospital of Essen,  
University of Duisburg-Essen,  
3University of Wuerzburg,  
1Belarus 
2,3Germany  
1. Introduction 
Papillary thyroid carcinoma (PTC) in children and adolescents is a medical problem that 
attracts attention of investigators and clinicians primarily because of the high incidence of 
this malignancy in individuals exposed to radioactive isotopes of iodine in case of nuclear 
reactor emergencies. New facts uncovered by various research groups make it possible to 
see the clinical and pathological peculiarities of these tumours in a new light and suggest 
that the aetiology can modify the biological behaviour of PTC. In particular, relative 
monomorphism of the structure of post-Chernobyl cancers was detected and morphology 
varies depending on the patients’ age and the time of radiation exposure (LiVolsi et al., 
2011).  
For 25 years now child and adolescent thyroid cancer patients with and without a history of 
radiation exposure were concentrated in the Republican Thyroid Cancer Centre in Minsk 
where they undergo diagnostics, treatment and follow-up (Demidchik et al., 2006). This 
presents a unique opportunity to compare cases depending on the presumed cancer 
aetiology and to analyze similarities and differences in the molecular-genetic background of 
carcinogenesis, morphological structure and extension of these tumours. 
The purpose of this study was to look into PTC in childhood and adolescence. We analyzed 
children between 1 and 14 years of age and adolescents between 15 and 18 years of age who 
were not exposed to known carcinogenic risks such as irradiation and did not have any 
indications of hereditary thyroid cancers (e.g. specifically cribriform-morular architecture). 
The second group consisted of patients of the same age in whom second primary papillary 
cancers of thyroid developed during the surveillance for primary malignancies in other 
organs or systems that were treated with external irradiation and/or chemotherapy. The 
third group, containing the largest number of PTC cases, consisted of children and 
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adolescents with the history of exposure to radioactive isotopes of iodine in the framework 
of the Chernobyl Reactor Accident in 1986.  
1.1 Epidemiology  
Thyroid cancer is uncommon in childhood and adolescence. The incidence of all thyroid 
cancer types in children and adolescents varies from 0.04-0.17 per 100 000 in Ukraine, 
Germany, and Russia up to 0.54 in the USA (Hogan et al., 2009; Machens et al., 2010; 
Romanchishen et al., 2008; Tronko et al., 1999). The age-specific rates differ in paediatric age 
subgroups, for example, in Canada it is 0.2 per 100 000 children at the age of 5-9 years and 
0.4 at the age of 10-14 years (O’Gorman et al., 2009), in USA 0.09 and 0.44 correspondingly 
(Hogan et al., 2009).  
In Belarus, the incidence of thyroid carcinoma in children has been increasing since 1990 and 
a case-control study established a connection between this raise and the effect of the 
radioiodine that was released as a result of the Chernobyl accident (Astakhova et al., 1998; 
Kazakov et al., 1992; E.P. Demidchik et al., 1994, 2002; Yu.E. Demidchik et al., 2007). The 
highest rate of paediatric thyroid cancer was registered in 1995 at 3.29 per 100 000 for the 
whole country and 10.5 per 100 000 in southern regions of Belarus (e.g. Gomel). This was 
followed later by a marked decline of the age-standardized rate and was 0.14 per 100,000 
(Savva et al., 2008). The proportion of PTC amid thyroid malignancies in the childhood 
population of Belarus was 87% in 1989-1997 (Steliarova-Foucher et al., 2006). It need to be 
clarified that after the demise of follicular carcinoma (major revision was done as the criteria 
that were used in soviet pathology practice since 1960es were abandoned after the training 
under supervision of leading westerner thyropathologists at the beginning of 1990es) the 
real numbers of PTC is close to 100%. 
However, even more recently (2005-2008) the thyroid carcinoma incidence rate (IR) in 
patients under 18 in Belarus amounts to 1.29 per 100 000. Thus, paediatric thyroid cancer 
incidence is still high in Belarus among radiation-exposed and unexposed patients (Fig.1). 
The majority of studies addressing the clinical and pathological characteristics of childhood 
thyroid carcinoma have reported on less than 100 cases, even if all types of thyroid cancer 
(sporadic, radiogenic and genetically determined) were included (Dinauer et al., 1998; 
Grigsby et al., 2002; Machens et al., 2010; O’Gorman et al., 2010). Moreover, some studies 
extended the patients’ age to 19 and 20 (Dinauer et al., 1998; Romanchishen et al., 2008) and 
thus only partially meet the criteria of childhood thyroid cancer.  
2. Diagnostics 
In Belarus, mass screening using mobile teams and prophylactic examinations in schools 
and outpatient clinics was started in 1987. Prior to 1987 the diagnosis of thyroid disease was 
based primarily on clinical evaluation with particular attention to risk factors, which 
clinicians took into account: the history of radiation exposure, genetic predisposition, age, 
gender, lymph nodes status, tracheal or vascular pressure symptoms, recurrent nerve palsy 
and thyroid nodule features (size, consistency and fixation). Currently in Belarus, thyroid 
carcinomas in the exposed population are frequently diagnosed using screening by 
ultrasound and fine needle aspiration biopsy. This method allows detection of small thyroid  
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Fig. 1. Annual incidence (per 100 000) of thyroid cancer in Belarus 
nodules, including microcarcinomas. Reported sensitivity, accuracy and specificity of this 
approach are equal to 90-100%, 80-95% and 80-100% respectively in cases of papillary 
carcinomas. Follicular carcinomas can rarely be diagnosed outright by ultrasound-guided 
fine needle aspiration biopsy as even positive data are reliable in less than 10% of cases 
(Chang et al., 2006; Sangalli et al., 2006; Florentine et al., 2006) 
The evaluation of patients with thyroid nodules included determining possible predisposing 
factors, evaluation of present complaints, clinical findings, thyroid function tests, 
thyroglobulin (Tg) levels, anti-TPO, anti-microsomal and anti-Tg antibodies, imaging 
procedures (cervical ultrasound scan, chest radiograph, computed tomography scan), and 
the cytological findings yielded with fine needle aspiration cytology. One diagnostic 
problem was determining the presence of thyroid cancer in the presence of coexisting 
multinodular goiter. These patients usually received TSH suppressive therapy with 
levothyroxine. Dynamic ultrasound examination permitted recognizing structural changes 
such as enlargement of thyroid nodules or enlarged neck lymph nodes. These signs were 
suspicious of malignancy. Symptomatic patients usually complained of a neck mass (12.3%). 
Less commonly (2.8%) there were signs of hypothyroidism. In only 0.5% of cases were 
symptoms of advanced carcinoma (as e.g. hoarseness or problems with swallowing) 
recorded.  
Preoperative work-up of patients suspected to have thyroid cancer included staging by 
computed tomography, MRI, thyroid scintigraphy with 131I and serum thyroglobulin 
measurements. Typically, intraoperative frozen sections made it possible to diagnose the 
majority of papillary carcinomas. 
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PTC got its name because of its peculiarity to build papillary structures like cauliflower 
vegetations, connective tissue stalks which have small blood and lymphatic vessels. There is 
also frequent connection of classic papillary formations with zones of follicular and solid 
structures, besides there are some carcinomas in which there are no papillas at all.  
Classification of PTC is made up taking into consideration various principles. Due to the 
peculiarities of tumour architecture investigators point out papillary, follicular, solid (solid- 
alveolar) and combined variants of structure. If we delved deeply from tissue to cell level, 
PTC can be classified according to the ability of cytoplasm stained by hematoxylin and eosin 
(common, clear and oxyphilic variants) and according to nuclear - cytoplasmic correlation 
(tall and columnar cell variants). At last, PTC can be divided according to the size 
(microcarcinoma) and growth essentials (solitary, multifocal and diffuse forms). 
Many investigators tried to correlate clinical and morphological signs taking into 
consideration variants of PTC according to the WHO histological classification. For instance, 
the thyroid tumours that were discovered after the Chernobyl nuclear accident were 
virtually all of the papillary type (95%). Within the papillary group several subtypes were 
noted including classical or usual type, follicular and solid variants and mixed patterns. 
Diffuse sclerosing distribution, cribriform/morular type and Warthin-like variant were rare. 
No tall cell or columnar cell forms were identified (LiVolsi, 2011). To our opinion a potential 
bias of this conclusion lays in interobserver variability and lack of distinct borders for 
designation of this or that PTC variant. Thus, before comparing different forms of thyroid 
cancer in children and adolescents, it is necessary to dwell on definitions which were used 
in reports and subsequent analysis of the material. 
Classical PTC is characterized by the formation of papillae made up of fibrovascular cores 
lined by one or two layers of neoplastic cells with a distinctive set of nuclear features which 
includes enlargement, elongation, clearing, thickened nuclear membranes, intranuclear 
cytoplasmic pseudoinclusions, nuclear grooves and small nucleoli closely opposed to the 
nuclear membrane. This pattern was usually mixed with the solid and follicular areas 
(DeLellies, R.A. & Williams, 2004). 
The follicular variant of papillary thyroid carcinoma is almost exclusively arranged in 
follicles (without papillae formation but small solid areas are not unusual) lined by cells 
with characteristic PTC nuclei and usually presents as an encapsulated or circumscribed 
tumour with pushing borders and less commonly as a partially/non-encapsulated 
infiltrative neoplasm.  
The solid variant is recognized by predominantly solid areas or a nested pattern of growth 
with prominent intratumoural capillary networks. These represent more than 50% of the 
tumour mass and can be associated with the follicular structures and even classic papillary 
vegetations. 
Tall-cell variant (TCV) of papillary thyroid carcinoma is defined as being composed largely 
of tall cells with height at least twice the width and eosinophilic cytoplasm as well as basally 
oriented nuclei (many of them contain large intranuclear cytoplasmic eosinophilic 
pseudoinclusions). These cells represent 50% or more of the papillary carcinoma cells to 
make the diagnosis of tall cell variant (Morris et al., 2010). In paediatric cases we have seen 
predominantly follicular and solid areas composed of tall-cell PTC nuclei. 
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Diffuse sclerosing variant of PTC (DSV) is characterized by diffuse involvement of one or 
both lobes, extensive sclerosis, numerous psammoma bodies, typical papillary carcinoma 
elements, widespread squamous metaplastic changes and dense lymphocytic infiltration. 
Some cases had dominant tumour mass of conventional papillary carcinoma with 
prominent fibrosis. We observed formed lymphoid follicles, intensive lymphoplasmacytic 
infiltration, diffuse scattered psammoma bodies and tumour emboli in lymphatic channels 
and in surrounding normal-looking thyroid gland. These particular tumours more likely 
represent the early phase of classical DSV. In our investigation we define such designation 
as ‘beginning‘DSV or monofocal PTC with DSV-like intrathyroidal dissemination. 
Diagnostic criteria for extrathyroidal extension and multifocal growth are important for 
staging of the disease. Some pathologists believe that the presence of adipose tissue within 
the normal thyroid gland and its pseudocapsule implies that thyroid carcinoma complexes 
within fat tissue cannot be accepted as a criterion of extrathyroidal extension (Mete O. et al., 
2010). To skip controversies surrounding diagnostic criteria we divided extrathyroidal 
extension in tables as in a case of invasion of skeletal muscle and fat tissue as well. The 
differences in estimation of the prevalence of multifocality across studies may be explained 
by the conflicting definitions used for multifocality and multicentricity. This inconsistency 
makes it difficult to analyze the literature on the subject. Some professionals consider 
tumour emboli in lymphatic channels as ‘multifocality’. To our opinion, this phenomenon 
should be diagnosed only in true multicentric transformation of the follicular epithelium (in 
case of independent clonal proliferations). Some situations are difficult to interpret without 
molecular investigation but tumours that differ from each other by anatomical sites and/or 
morphological structure and accompanied by fibrosis we define as multifocal. On the other 
hand, glands with a large clinical papillary cancer and multiple small intrathyroidal foci are 
‘lymphatic spread‘. 
3. Treatment  
Optimal treatment of thyroid cancer in patients of any age includes surgery, radioiodine 
therapy for ablation of the thyroid remnant or treatment of distant metastases and 
levothyroxine suppressive therapy (Reiners & Demidchik, 2003; Luster et al., 2007; Reiners 
et al., 2008, 2009).  
Patients with the history of exposure to radiation are considered as a high risk group (Clark, 
2005). This point of view is based on the assumption that radionuclides of iodine affect the 
whole thyroid gland with an increased risk of multifocality. Therefore, the risk of tumour 
relapse in the thyroid remnant after partial resection is theoretically higher than in patients 
with sporadic carcinomas. There are many studies about the technique of operative 
intervention in patients with thyroid cancer. Today, prognostic factors for this disease have 
been carefully studied and treatment methods have been improved. Total thyroidectomy is 
considered the procedure of choice in patients with multifocal cancers, large tumour size, 
extrathyroidal extension and regional or distant metastasis. One important reason for 
recommending a total thyroidectomy is to faciliatate the ablation of the thyroid remnant and 
treatment of local or distant metastases with radioiodine (Luster et al., 2007; Reiners, 2009). 
Survival rates and quality of life of patients after surgical treatment remain high even in 
those cases when the findings at surgery reveal invasive carcinomas with involvement of 
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adjacent organs and tissue structures of the neck (Gilliland et al., 1997, Lerch et al., 1997, 
Schlumberger, 2001, Shaha et al., 1997).  
4. Comparative clinical and morphological analysis of sporadic papillary 
thyroid cancer, PTC as second malignancy and post-Chernobyl PTC  
We define cancers as possibly radiation induced that developed in patients exposed to 
radioiodine in the context of the Chernobyl accident (this process was completed by June 
1986). Therefore, for all patients in the sporadic group born after February 1987 (the eldest of 
which was 18 in 2005), the fall-out from Chernobyl likely did not play a role in thyroid 
carcinogenesis (LiVolsi et al., 2011). As a third group, we consider patients with second 
primaries of the thyroid that developed after treatment for another preceding primary 
malignancy. In the context of thyroid cancer external irradiation and probably the effect of 
chemotherapeutic agents for the combined therapy of hemoblastosis and other neoplasms in 
childhood have to be taken into consideration (Acharya et al., 2003; LiVolsi et al., 2011; 
Naing et al., 2009; Seaberg et al., 2005; Taylor et al., 2009). 
4.1 Sporadic cancer 
We analyzed 150 children and adolescents who had sporadic PTC (118 girls and 32 boys - 3.7:1 
- aged from 4 to 18 years inclusively). Most patients underwent total thyroidectomy (126; 
84.0%) or lobectomy (21; 14.0%) with simultaneous lymph node removal (133; 88.7%) on one or 
both sides of the neck. Lymph node central neck dissection included excision of level VI; 
bilateral selective or modified radical neck dissection was also performed (levels  
II – V). The number of removed lymph nodes varied from 1 to 87. In the latter part of the study 
the majority of patients (83; 55.3%) received radioiodine therapy for thyroid remnant ablation 
(75; 50.0%) with an average activity of 3.7 (0.31-9.44) GBq. In patients with lung metastases (8; 
5.3%) a higher average activity of 7.42 (5.5-12.89) GBq of radioiodine was delivered. In all 
children and adolescents, TSH suppressive therapy was used as part of the treatment. The 
average follow-up time for patients in this group was 66.0 months (29.7-303.3). 
Clinical and pathologic data on 150 patients with sporadic PTC is presented in Table 1.  
The median size of sporadic carcinoma tumour nodules was 12 (1-100) mm both for children 
and adolescents. Total involvement of thyroid gland was observed among the patients that 
suffered from diffuse sclerosing PTC and the maximum tumour size made up 100 mm. The 
tumour dimension surpassed 10 mm in 49 (62.8%) of children and 43 (59.7%) adolescents. 
Lung metastases (children; 8 cases, 10.3%) and multifocal growth (children and adolescents, 
5 cases, 3.3%) were rare. 
Classical type of PTC that included pure papillary or mixture of patterns dominated both in 
children (25; 32.1%) and adolescents (36; 50.0%) followed by follicular and tall cell variants. 
Extrathyroidal extension took place in one of every three patients (children and adolescents, 
49; 32.7%). PTC involved veins (29; 19.3%) and lymph vessels (120; 80.0%) in one of every 
five children and adolescents (tumour complexes and/or psammoma bodies, 4 of 5 cases).  
PTC was more likely to develop in the background of asymptomatic autoimmune 
thyroiditis that was evenly distributed in all age groups (21 of 78 children, 26.9%; 17 of 72 
adolescents, 26.4%). 
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 Age groups, years at presentation 
Total (n=150) 
4-14 years (n=78) 15-18 years (n=72) 
Age at diagnosis,     
mean± SD  11.8±2.2 16.1±1.0 13.8±2.8 
Gender (girls: boys) 2.5:1 6.2:1 3.7:1 
girls 
boys 
56 (71.8%) 
22 (28.2%) 
62 (86.1%) 
10 (13.9%) 
118 (78.7%) 
32 (21.3%) 
Tumour size, mm 
median (range) 
 
12.0 (1-100) 
 
11.5 (3-58) 
 
12.0 (1-100) 
≤10 mm 
1-5 mm 
6-10 mm 
29 (37.2%) 
5(6.4%) 
24 (30.8%) 
29 (40.3%) 
12 (16.7%) 
17 (23.6%) 
58 (38.7%) 
17 (11.4%) 
41 (27.3%) 
≥11 mm 49(62.8%) 43(59.7%) 92(61.3%) 
Localization    
Subcapsular 
Inside lobe 
Isthmus 
36 (46.2%) 
37 (47.4%) 
5 (6.4%) 
18 (25.0%) 
46 (63.8%) 
8 (11.2%) 
54 (36.0%)  
83 (55.4%) 
13 (8.6%) 
 Local spreading, N0: 19(24.3%) 23 (31.5%) 42 (28.0%) 
intrathyroidal 
extrathyroidal 
not reported, pTx 
10 (12.8%) 
4 (5.1%) 
5 (6.4%) 
15 (20.8%) 
4 (5.6%) 
4 (5.6%) 
25 (16.7%) 
8 (5.3%) 
9 (6.0%) 
Regional spreading, N+: 59(75.7%) 49 (68.0%) 108 (72.0%) 
N1a 
N1b 
N1b unilateral 
N1b bilateral 
10 (12.8%) 
49 (62.8%) 
31(39.7%) 
18(23.1%) 
17 (23.6%) 
32 (44.4%) 
28 (38.9%) 
4 (5.6%) 
27 (18.0%) 
81 (54.0%) 
59 (39.3%) 
19 (12.7%) 
Distant metastases, M1  
(lungs) 
8 (10.3%) 0 8 (5.3%) 
Tumour histology 
(predominant architecture): 
   
Papillary 
Follicular 
Solid  
28 (35.9%) 
29 (37.2%) 
21 (26.9%) 
31 (43.0%) 
28 (38.9%) 
13 (18.1%) 
59 (39.3%) 
57 (38.0%) 
34 (22.7%) 
Histological types:    
Classical PTC 
Follicular 
Diffuse sclerosing (DSV) 
Monofocal with diffuse 
sclerosing involvement 
(DSV-like) 
Tall cell 
Solid  
25 (32.1%) 
16 (20.5%) 
5 (6.4%) 
 
10 (12.8%) 
 
11 (14.1%) 
11 (14.1%) 
36 (50%) 
15 (20.9%) 
4 (5.5%) 
 
2 (2.8%) 
 
8 (11.1%) 
7 (9.7%) 
61 (40.7%) 
31 (20.7%) 
9 (6.0%) 
 
12 (8.0%) 
 
19 (12.6%) 
18 (12.0%) 
Multifocal growth 3 (3.9%) 2 (2.8%) 5 (3.3%) 
Morphological  
specifications: 
   
Infiltrative growth 
1. Intrathyroidal (pT1-T2)
2. Extrathyroidal 
extension (pT3) 
in fat tissue 
in muscle 
        3. pTx 
57 (73.1%) 
17 (21.8%) 
 
31 (39.7%) 
29 (37.2%) 
2 (2.5%) 
       9 (11.5%) 
54 (75.0%) 
20 (27.8%) 
 
18 (25.0%) 
16 (22.2%) 
2 (2.8%) 
          16 (22.2%) 
111 (74.0%) 
37 (24.7%) 
 
49 (32.7%) 
45 (30.0%) 
4 (2.7%) 
      25 (16.7%) 
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circumscribed/encapsulated 
growth (pT1, pT2, pTx) 
 
7 (9.0%) 
 
11 (15.3%) 
 
18 (12.0%) 
Diffuse involvement (DSV 
and DSV-like – pT1-pTx) 
14 (17.9%) 7 (9.7%) 21 (14.0%) 
Intratumoural fibrosis:    
Focal 48 (52.0%) 37 (51.4%) 85 (56.7%) 
Septal 6 (8.0%) 13 (18.1%) 19 (12.7%) 
Massive (central scarring) 25 (32.0%) 19 (26.4%) 44 (29.3%) 
Blood vessels involvement 20 (25.6%) 9 (12.5%) 29 (19.3%) 
Lymph vessels involvement 66 (84.6%) 54 (75%) 120 (80%) 
Nodular type of mononuclear 
infiltration 
20 (25.6%) 13 (18.0%) 33 (22.0%) 
Sparse mononuclear 
infiltration 
35 (44.9%) 39 (54.2%) 74 (49.3%) 
Comorbidity: 
Autoimmune thyroiditis 
Follicular adenoma 
Nodular goitre 
 
21 (26.9%) 
0 
0 
 
17 (26.4%) 
3 (4.2%) 
4 (5.5%) 
 
38 (25.3%) 
3 (2.0 %) 
4 (2.7%) 
Treatment:    
Surgical: 
Total thyroidectomy  
Lobectomy   
Resection  
 
65 (83.3%) 
13 (16.7%) 
0 
 
61 (84.7%) 
8 (11.1%) 
3 (4.2%) 
 
126 (84.0%) 
21 (14.0%) 
3 (2.0%) 
Neck dissection 67(85.9%) 66(91.7%) 133(88.7%) 
Number of dissected cervical 
lymph nodes /N+ 
median (range) 
26 (2-87)/4 (1-77) 22 (1-65)/1 (1-18) 24 (1-87)/3 (1-77) 
I-131 therapy: 
ablation (GBq) 
median (range) 
 
n=41 
4.0 (0.61-9.44) 
 
n=34 
3.48 (0.31-6.7) 
 
n=75 
3.7 (0.31-9.44) 
treatment for lung 
metastases (GBq), median 
(range) 
n=8 
7.42 (5.5-12.89) 
 
- 
n=8 
7.42 (5.5-12.89) 
Follow-up, months 
median (range) 
 
79.35  
(29.72-303.25) 
57.22  
(29.69-102.9) 
66.03  
(29.69-303.25) 
Table 1. Clinical and pathologic features of sporadic PTC  
The distribution of TNM tumour stages according to tumour size of sporadic PTC is shown 
in Table 2.  
The most striking feature of this comparison is the high rate of extrathyroidal extension 
(patients in pT3 stage observed in 40.0%) and lymph node metastases (N1 discovered in 
72.0%). However, it is easy to understand that even small tumours within the size of up to 
10 mm corresponding to a volume of 0.5 ml which is too large to be harboured in the small 
thyroid lobe of a young child with a volume of less than 2 ml (Farahati et al., 1999). 
The inability to define the T-category (pTx observed in 36 patients. 24.0%) can largely be 
attributed to surgeons or pathologists sectioning the specimen prior to it being properly 
processed. This fact draws attention to the necessity to follow strict rules while dealing with 
thyroid carcinomas and illustrates the need for standardization of sampling: removed parts  
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pT/tumour size N0 N1a N1b Total M0 M1 
T1a (1-10mm)  14 (9.3%) 10 (6.7%) 9 (6.0%) 33 (22.0%) 33 (22.0%) 0 
     1-5mm  6 (4.0%) 5 (3.3%) 2 (1.0%) 13 (8.7%) 13 (8.7%) 0 
     6-10mm  8 (5.3%) 5 (3.3%) 7 (4.7%) 20 (13.3%) 20 (13.3%) 0 
pT1b(11-20mm) 9 (6.0%) 2 (1.0%) 8 (5.3%) 19 (13.0%) 19 (13.0%) 0 
pT2 (21-40mm) 2 (1.0%) 0 0 2 (1.0%) 2 (1.0%) 0 
pT3  8 (5.3%) 8 (5.3%) 44 (29.3%) 60 (40.0%) 52 (34.7%) 8 (5.3%) 
      1-10mm  3 (2.0%) 5 (3.3%) 9 (6.0%) 17 (11.3%) 16 (10.7%) 1 (0.6%) 
      ≥11 mm  5 (3.3%) 3 (2.0%) 35 (23.3%) 43 (28.7%) 36 (24.0%) 7 (4.7%) 
pTx  9 (6.0%) 7 (4.7%) 20 (13.3%) 36 (24.0%) 36 (24.0%)    0 
     1-10mm  3 (2.0%) 2 (1.0%) 4 (2.7%) 9 (6.0%) 9 (6.0%)    0 
   ≥11 mm  6 (4.0%) 5 (3.3%) 16 (10.7%) 27 (18.0%) 27 (18.0%)    0 
n (%) 42 (28.0%) 27 (18.0%) 81 (54.0%) 150 (100%) 142 (94.7%) 8 (5.3%) 
Table 2. Tumour size, lymph node and distant metastases in children and adolescence with 
sporadic PTC (according to AJCC/UICC TNM. 7th edition) 
of the thyroid gland should be sectioned by the pathologist only along cephalocaudal axis 
(from the upper to the lower pole in vertical plane). 
4.2 Second primary thyroid cancer 
There were 34 patients with the second primary malignant thyroid tumour in the follow-up 
period from 1995 to 2010, where PTC was detected in 32 individuals (94.1%). One person 
had medullary carcinoma and the other one suffered from poorly differentiated cancer. 
Only 23 from 32 cases of PTC (10 girls and 13 boys) were enrolled into the study because the 
tumour in the thyroid gland was diagnosed at the age of 8-18 years. In seven cases primary 
metachronous papillary cancer developed when the patients were aged 19-32 years. Finally, 
two adolescents underwent treatment for brain neoplasms (astrocytoma and 
medulloblastoma) at the age of 4-8 and were excluded from the study due to the fact that 
thyroid tumours had cribriform morular structures (generative mutation of APC-gene, 
Turcot syndrome, was detected in 1 case). 
The first primary malignancy was detected in the patients at a median age of 4.7 years (1-12 
years). Median latent period till the second tumour (thyroid cancer) was 9.2 years (4-16 
years). 
Treatment for the first malignant neoplasm (hemoblastosis, sarcoma, medulloblastoma) was 
provided in accordance with the standard protocols. External irradiation was used in all the 
cases (the total absorbed doses for the primary tumour varied from 12 to 54 Gy). Surgical 
and postoperative treatment of thyroid carcinomas was also standardized: as a rule, total 
thyroidectomy (21; 91.4%) with bilateral neck dissection (in 21 of 23 patients. 91.3%) was 
performed. Thirteen patients underwent from 1 to 4 ablative courses of radioiodine therapy 
(average activity 4.36 GBq, 0.3-7.8 GBq). In one case a patient who was previously treated 
for Hodgkin’s lymphoma at the age of 3.6, five years later the diffuse sclerosing variant of 
PTC (pT3N1bM1) with distant metastases to lungs was diagnosed and treated with 4 
courses of radioiodine therapy (13.6 GBq) after surgery.  
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Eleven of 23 patients with secondary papillary cancer had been treated previously for 
malignant lymphoma (9 patients with Hodgkin’s disease). In seven patients leukaemia 
was the primary malignancy (acute myeloblastic leukaemia was diagnosed in one patient 
who died of sepsis which was in progress while treating the third recurrence of 
hemoblastosis). Acute lymphoblastic leukemia was diagnosed in six patients. These data 
are in accordance with the observation that the risk of second primary malignancy in the 
thyroid is much higher if Hodgkin disease, non-Hodgkins lymphoma or leukemia has 
been the primary malignancy (Meadows et al., 2009). One patient with medulloblastoma 
was cured. Three more girls and one boy had soft tissue malignancies of the head, neck 
and urinary bladder. The last patient was diagnosed with embryonal rhabdomyosarcoma 
of the urinary bladder which was detected at the age of 1.4. He then developed an 
astrocytoma of the brainstem 14 years later and PTC was detected two years after brain 
tumour at the age of 17.  
For patients who developed PTC after treatment for lymphoma, the latent period from 
completion of lymphoma treatment till verification of papillary thyroid cancer was 8.6 years 
(5 to 13 years). The median period until the development of PTC for the patients with 
leukemia was 6.9 years (4 to 12 years) and for patients with soft tissue tumours the latency 
was a median of 14.0 years (10 to 16 years). 
As a rule, thyroid malignancies are likely to develop after irradiation of the neck. However, 
combined treatment was carried out in the case of embryonal rhabdomyosarcoma of urinary 
bladder (according to the protocol CWS-91), which consisted of irradiation of the 
suprapubic area with a total absorbed dose of 40 Gy and chemotherapy with vincristine, 
doxorubicin, cyclophosphamide, actinomycin D and ifosfamide. In 1992 it may have been 
impossible to provide complete protection of the neck while irradiating a one-year old child, 
and this may have contributed to the development of papillary thyroid carcinoma after 16 
years, though alternative hypotheses must also be considered.  
It should be noted that one patient was subjected to unusual aggressive external 
irradiation. This female was diagnosed to have aggressive fibromatosis involving soft 
tissues around right scapulae in May 1985 that was removed. Then, from January to 
March 1986, the patient was treated for tumour relapse (three lumps 5х4, 6х6 and 4х3cm) 
which required removal of the medial part and lower corner of the right scapular bone, 
right sided VI-VIII ribs and adjacent soft tissues. In addition, postoperative irradiation 
was carried out with 40 Gy at the right scapula and 16 Gy at the left supraclavicular area 
(February-March 1986). In April 1986, new nodule of irregular shape in soft tissues of 
lumbar spine was detected with the size of 8х1.5 cm. After radiation therapy with the 
dose of 60 Gy (15/04-19/05 1986) the tumour became 5х3.5 cm. In July of the same year 
besides a paravertebral tumour located in soft tissues at level D10-D11 another tumour 
6х5.5 cm appeared in the area of medial side of the left scapula. The patient was exposed 
to irradiation again with the dose of 46 Gy. In November 1996, a tumour in the right lobe 
of thyroid gland was detected and lobectomy with isthmus resection was carried out 
(follicular thyroid cancer with minimal invasion of the capsule was diagnosed; later it was 
reclassified as a follicular variant of PTC).  
A few relapses of desmoid tumour still took place: nodules in gluteus on the right and left 
sides (removed and irradiated with a dose of 60 Gy), a lump in the right thigh treated with 
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hyper fractionated external beam therapy with a total absorbed dose of 25 Gy. The area of 
the right thigh and iliac nodes additionally were irradiated with 60 Gy. The patient then got 
chemotherapy with cyclophosphamide (1500 mg) and cisplatin (120 mg) from October 1998 
to March 1999 (4 courses). The treatment failed to stabilize the progress, and there were 
further relapses in 2001 and 2006 that led to surgical excision of the long head of the right 
side biceps (nodule 7.5х6.0х2.8 cm) and consecutive radiotherapy with 40 Gy again. At 
present, there is no progression of both tumours and the patient gets substitutive hormonal 
treatment for thyroid carcinoma.  
Clinical and pathologic data for the 23 patients with PTC as a second primary malignancy 
are presented in Table 3.  
 
Characteristics 
Age groups,  years at presentation 
Total (n=23) 
4-14 years (n=10) 15-18 years (n=13) 
Age at diagnosis.     
mean± SD  11.0±2.0 16.3±1.2 14.0±3.1 
Sex (girls: boys) 1:1 1:1.6 1:1.3 
girls 
boys 
5 (50%) 
5 (50%) 
5 (38.5%) 
8 (61.5%) 
10 (43.5%) 
13 (56.5%) 
Tumour size, mm 
median (range) 
 
10 (8-50) 
 
10 (3-45) 
 
10 (3-50) 
≤10 mm 
1-5 mm 
6-10 mm 
6 (60%) 
0 
6 (60%) 
8 (61.5%) 
2 (15.4%) 
6 (46.1%) 
14 (60.9%) 
2 (8.7%) 
12 (52.2%) 
≥11 mm 4 (40%) 5 (38.5%) 9 (39.1%) 
Localization:    
Subcapsular 
Inside lobe 
Isthmus 
6 (60%) 
2 (20%) 
2 (20%) 
8 (61.5%) 
5 (38.5%) 
0 
14 (60.9%) 
7 (30.4%) 
2 (8.7%) 
 Local spreading, N0: 1 (10%) 5 (38.5%) 6 (26.1%) 
intrathyroidal 
extrathyroidal 
not-reported, pTx 
1 (10%) 
0 
0 
3 (23.1%) 
2 (15.4%) 
0 
4 (17.4%) 
2 (8.7%) 
0 
Regional spreading, N+: 9 (90%) 8 (61.5%) 17 (73.9%) 
N1a 
N1b 
N1b unilateral 
N1b bilateral 
5 (50%) 
4 (40%) 
3 (30%) 
1 (10%) 
5 (38.5%) 
3 (23.1%) 
3 (23.1%) 
0 
10 (43.5%) 
7 (30.4%) 
6 (26.1%) 
1 (4.3%) 
Distant metastases, M1  
(lungs) 
1 (10%) 0 1 (4.3%) 
Tumour histology 
(predominant architecture): 
   
Papillary 
Follicular 
Solid  
3 (30%) 
5 (50%) 
2 (20%) 
6 (46.2%) 
6 (46.2%) 
1 (7.7%) 
9 (39.1%) 
11 (47.8%) 
3 (13.1%) 
Histological types:    
Classical PTC 
Follicular 
Diffuse sclerosing (DSV) 
Monofocal with diffuse 
sclerosing involvement 
4 (40%) 
2 (20%) 
1 (10%) 
 
1 (10%) 
4 (30.8%) 
3 (23.1%) 
1 (7.7%) 
 
1 (7.7%) 
8 (34.8%) 
5 (21.7%) 
2 (8.6%) 
 
2 (8.6%) 
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Characteristics 
Age groups,  years at presentation 
Total (n=23) 
4-14 years (n=10) 15-18 years (n=13) 
(DSV-like) 
Tall cell 
Solid  
 
0 
2 (20%) 
 
3 (23.1%) 
1 (7.7%) 
 
3 (13%) 
3 (13%) 
Multifocal  growth 0 0 0 
Morphological specifications:    
Infiltrative growth 
1. Intrathyroidal  
(pT1-T2) 
2. extrathyroidal 
extension (pT3) 
in fat tissue 
in muscle 
8 (80%) 
2 (20%) 
6 (60%) 
 
6 (60%) 
0 
8 (61.5%) 
1 (7.7%) 
7 (53.9%) 
 
7 (53.9%) 
0 
16 (69.8%) 
3 (13%) 
13 (56.8%) 
 
13 (56.8%) 
0 
circumscribed/encapsulate
d growth 
0 3 (23.1%) 3 (13%) 
Diffuse involvement (DSV 
and DSV-like) 
2 (20%) 2 (15.4%) 4 (17.2%) 
Intratumoural fibrosis:    
Focal 4 (40%) 7 (53.9%) 11 (47.8%) 
Septal 3 (30%) 3 (23.1%) 6 (26.1%) 
Massive (central 
scarring) 
3 (30%) 1 (7.7%) 4 (17.2%) 
Blood vessel involvement 5 (50%) 3 (23.1%) 8 (34.8%) 
Lymph vessel involvement 9 (90%) 9 (69.3%) 18 (78.3%) 
Nodular type of mononuclear 
infiltration 
2 (20%) 2 (15.4%) 4 (17.2%) 
Sparse mononuclear 
infiltration 
6 (60%) 11 (84.7%) 17 (73.9%) 
Comorbidity: 
Autoimmune thyroiditis 
Follicular adenoma 
Nodular goitre 
 
0 
0 
0 
 
0 
0 
1 (7.7%) 
 
0 
0 
1 (4.3%) 
Treatment 
Surgical: 
Total thyroidectomy  
Lobectomy  
Resection  
 
 
10 (100%) 
0 
0 
 
 
11 (84.7%) 
1 (7.7%) 
1 (7.7%) 
 
 
21 (91.4%) 
1 (4.3%) 
1 (4.3%) 
neck dissection 10 (100%) 10 (77%) 20 (87%) 
number of dissected cervical 
lymph nodes /N+ 
median (range) 
21 (6-64)/5 (1-18) 13 (3-39)/1 (1-18) 19 (3-64)/3 (1-18) 
Ablation (GBq) 
median (range) 
n=7 
4.36 (2.1-7.805) 
n=6 
4.59 (0.307-7.696) 
n=13 
4.36 (0.307-7.805) 
Treatment for lung 
metastases (GBq), median 
(range) 
 
13.352±NA 
 
- 
 
13.352±NA 
Follow-up, months from the 
end of treatment for PTC 
median (range) 
 
 
104.99 (84.2-171.85) 
 
 
68.38 (18.15-186.64) 
 
 
99.35 (18.15-186.54) 
Table 3. Clinical and pathologic features of PTC as second primary malignancy 
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In sporadic cases of PTC (Table 1) the gender rate was different between children and 
adolescents with an increasing preponderance of females (from 2.5:1 to 6.2:1 accordingly). 
However, in second primary malignancies (females) these differences were not detected (1:1 
in children, 1:1.6 in adolescents). Another divergence with sporadic PTC was the complete 
absence of autoimmune thyroiditis in second primary thyroid cancers. With respect to the 
other characteristics, PTC as a second primary malignancy presented very similar to 
sporadic PTC. 
The distribution of TNM tumour stages according to tumour size of PTC as second primary 
malignancy is shown in Table 4.  
pT/tumour size N0  N1a  N1b  Total  M0 M1 
T1a (1-10mm)  1 (4.3%) 2 (8.7%) 0 3 (13.0%) 3 (13.0%) 0 
     1-5mm  1 (4.3%) 1 (4.3%) 0 2 (8.7%) 2 (8.7%) 0 
     6-10mm  0 1 (4.3%) 0 1 (4.3%) 1 (4.3%) 0 
pT1b (11-20mm) 3 (13.0%) 0 0 3 (13.0%) 3 (13.0%) 0 
pT2 (21-40mm) 0 0 0 0 0 0 
pT3  2 (8.7%) 8 (34.7%) 7 (30.4%) 17 (73.9%) 16 (69.6%) 1 (4.3%) 
      1-10mm  1 (4.3%) 6 (26.0%) 4 (17.4%) 11 (47.8%) 11 (47.8%) 0 
      ≥11 mm  1 (4.3%) 2 (8.7%) 3 (13.0%) 6 (26.1%) 5 (21.7%) 1 (4.3%) 
Total (%) 6 (26.0%) 10 (43.6%) 7 (30.4%) 23 (100.0%) 22 (95.7%) 1 (4.3%) 
Table 4. Tumour size, lymph nodes and distant metastases in children and adolescents with 
PTC as second primary malignancy according to AJCC/UICC TNM. 7th edition 
When comparing the extension of tumour disease in two groups (table 2 and 4) it should be 
noted that the majority of patients (74%) operated for sporadic PTC showed minimal 
extrathyroidal extension. The rate of local metastases was similar in both groups (72% vs. 
74%). Organ metastases were only observed in cases with extracapsular spread of thyroid 
carcinoma. 
4.3 Post-Chernobyl PTC 
The victims of the Chernobyl disaster represent a quite homogenous cohort. There is a 
general agreement now that the minimal latent period for the development of radiation-
induced thyroid cancer is approximately 4 years. The incidence of radiogenic thyroid 
carcinoma is higher in females (1.6:1). European findings also indicate that the number of 
cases of thyroid carcinoma in males is lower than in females (Farahati et al., 1997). The vast 
majority of radiation-associated thyroid cancers are PTC with a high incidence of 
extrathyroidal extension and lymph node metastases (49.1% and 64.6%, respectively). 
(Pacini et al., 1997; Williams et al., 2004; Williams et al.; 2008; Reiners et al. 2008).  
Clinical and pathologic data of 908 patients with post-Chernobyl PTC are presented in 
Table 5.  
As in the two previous groups, post-Chernobyl PTC cases are characterized by infiltrative 
growth (82.6%), a high rate of extrathyroidal extension (37.0%) and nodal metastases 
(74.4%). Multifocal growth was detected much more frequently (6.2%) than in children and 
adolescents with sporadic (3.3%) or second primary (0) carcinomas.  
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Characteristics 
Age groups, years at presentation 
Total (n=908) 
4-14 years (n=508) 15-18 years (n=400) 
Demographics  
Age at diagnosis,  
 
12.0±2.4 
 
16.8±1.1 
 
14.1±3.1 
mean± SD     
Gender (girls: boys) 1.6:1 2.0:1 1.88:1 
girls 
boys 
314 (61.8%) 
194 (38.2%) 
266 (66.5%) 
134 (33.5%) 
580 (63.9%) 
328 (36.1%) 
Tumour size. mm 
median (range) 
12 (1-85) 12 (1-124) 12 (1-124) 
≤10 mm 
1-5 mm 
6-10 mm 
199 (39.2%) 
16 (3.2%) 
183 (36.0%) 
178 (44.5%) 
43 (10.7%) 
135 (33.8%) 
377 (41.5%) 
59 (6.5%) 
318 (35.0%) 
≥11 mm 309 (60.8%) 222 (55.5%) 531 (58.5%) 
Localization:  
Subcapsular 
Inside lobe 
Isthmus 
245 (48.2%) 
239 (47.0%) 
24 (4.8%) 
198 (49.5%) 
177 (44.3%) 
25 (6.2%) 
443 (48.8%) 
416 (45.8%) 
49 (5.4%) 
 Local spreading, N0: 124 (24.4%) 109 (27.2%) 233 (25.7%) 
intrathyroidal 
extrathyroidal 
non-detected pTx 
53 (10.4%) 
22 (4.3%) 
49 (9.6%) 
73 (18.3%) 
15 (3.7%) 
21 (5.2%) 
126 (13.9%) 
37 (4.1%) 
70 (7.7%) 
Regional spreading. N+: 384 (75.6%) 291 (72.8%) 675 (74.4%) 
N1a 
N1b 
N1b unilateral 
N1b bilateral 
217 (42.7%) 
167 (32.9%) 
137 (27.0%) 
30 (5.9%) 
104 (26.0%) 
187 (46.8%) 
158 (39.5%) 
29 (7.3%) 
321 (35.3%) 
354 (39.1%) 
295 (32.5%) 
59 (6.5%) 
Distant metastases, M1 
(lungs)  
75 (14.8%) 28 (7.0%) 103 (11.3%) 
Tumour histology (predominant 
architecture): 
   
Papillary 
Follicular 
Solid  
138 (27.2%) 
253 (49.8%) 
117 (23.0%) 
154 (38.5%) 
191 (47.8%) 
55 (13.7%) 
292 (32.2%) 
444 (48.9%) 
172 (18.9%) 
Histological types:    
Classical PTC 
Follicular 
Diffuse sclerosing (DSV) 
Monofocal with diffuse 
sclerosing involvement (DSV-
like) 
Tall cell 
Solid  
Clear cell 
Oncocytic  
200 (39.4%) 
158 (31.1%) 
13 (2.6%) 
 
26 (5.1%) 
 
23 (4.5%) 
88 (17.3%) 
0 
0 
151 (37.8%) 
126 (31.5%) 
13 (3.3%) 
 
18 (4.5%) 
 
45 (11.3%) 
40 (10.0%) 
2 (0.5%) 
5 (1.1%) 
351 (38.7%) 
284 (31.3%) 
26 (2.9%) 
 
44 (4.8%) 
 
68 (7.5%) 
128 (14.1%) 
2 (0.2%) 
5 (0.6%) 
Multifocal  growth 22 (4.3%) 34 (8.5%) 56 (6.2%) 
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Characteristics 
Age groups, years at presentation 
Total (n=908) 
4-14 years (n=508) 15-18 years (n=400) 
Morphological specifications:  
Infiltrative growth 440 (86.6%) 310 (77.5%) 750 (82.6%) 
1. Intrathyroidal (pT1-T2) 
2. extrathyroidal extension 
(pT3) 
in fat tissue 
in muscle 
        3. pTx 
        4. pT4 
91 (17.9%) 
195 (38.4%) 
173 (34.1%)
22 (4.3%)
154 (30.3%) 
0 
106 (26.5%) 
 
141 (35.3%) 
136 (34.0%)
5 (1.3%)
62 (15.5%) 
1 (0.2%) 
197 (21.7%) 
 
336 (37.0%) 
309 (34.0%) 
27 (3.0%) 
216 (23.8%) 
1 (0.1%) 
circumscribed/encapsulated 
growth (pT1, pT2, pTx) 
 
Diffuse involvement  
DSV and DSV-like (pT1-pTx) 
29 (5.7%) 
 
 
39 (7.7%) 
59 (14.8%) 
 
 
31 (7.7%) 
88 (9.7%) 
 
 
70 (7.7%) 
Intratumoural fibrosis:    
Focal 217 (42.7%) 188 (47.0%) 405 (44.6%) 
Septal 86 (16.9%) 69 (17.3%) 155 (17.1%) 
Massive (central scarring) 190 (37.4%) 128 (32.0%) 318 (35.0%) 
Blood vessel involvement 105 (20.7%) 62 (15.5%) 167 (18.4%) 
Lymph vessel involvement 442 (87.0%) 316 (79.0%) 758 (83.5%) 
Nodular type of mononuclear 
infiltration 
76 (15.0%) 63 (15.8%) 139 (15.3%) 
Sparse mononuclear infiltration 394 (77.6%) 286 (71.5%) 680 (74.9%) 
Comorbidity: 
Autoimmune thyroiditis 
Follicular adenoma 
Nodular goitre 
 
25 (4.9%) 
9 (1.8%) 
16 (3.1%) 
 
43 (10.8%) 
10 (2.5%) 
32 (8.0%) 
 
68 (7.5%) 
19 (2.1%) 
48 (5.3%) 
Surgical treatment: 
Total thyroidectomy  
Lobectomy   
Resection  
 
306 (60.2%) 
182 (35.9%) 
20 (3.9%) 
 
315 (78.8%) 
76 (19.0%) 
9 (2.3) 
 
621 (68.4%) 
258 (28.4%) 
29 (3.2%) 
Neck dissection 435 (85.6%) 349 (87.3%) 784 (86.3%) 
Number of dissected cervical 
lymph nodes/N+ 
median  
 
8 (1-61)/3 (1-44) 
 
19 (1-95)/3 (1-46) 
 
12 (1-95)/ 
5 (1-46) 
 
Ablation (GBq) 
median (range) 
n=259 
5.2 (0.4-28.1) 
n=228 
4.9 (0.3-40.4) 
n=487 
5.1 (0.3-40.4) 
Treatment for lung metastases 
(GBq), median (range) 
n=95 
16.3 (1.2-52.9) 
n=33 
21.9 (2.4-60.5) 
n=128 
17.2 (1.2-60.5) 
Follow-up, months 
median (range) 
184.8  
(122.5-270.0) 
131.6  
(68.1-253.9) 
165.4  
(68.1-270.0) 
Table 5. Clinical and pathologic features of post-Chernobyl PTC  
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The distribution of TNM tumour stage according to tumour size of post-Chernobyl PTC is 
shown in the table 6.  
pT/tumour size N0 N1a N1b Total M0 M1 
T1a (1-10mm)  99 (10.9%) 46 (5.1%) 34 (3.8%) 179 (19.7) 178 (19.6%) 1 (0.1%) 
     1-5mm  47 (5.2%) 11 (1.2%) 5 (0.6%) 63 (6.9%) 63 (6.9%) 0 
     6-10mm 116 52 (5.7%) 35 (3.9%) 29 (3.2%) 116 (12.8%) 115 (12.7%) 1 (0.1%) 
pT1b (11-20mm) 27 (3.0%) 30 (3.3%) 29 (3.2%) 86 (9.5%) 86 (9.5%) 0 
pT2 (21-40mm) 1 (0.1%) 2 (0.2%) 3 (0.3%) 6 (0.7%) 6 (0.7%) 0 
pT3-4  39 (4.3%) 136 (15.0%) 205 (22.6%) 380 (40.9%) 303 (33.3%) 77 (8.5%) 
      1-10mm  23 (2.5%) 48 (5.3%) 37 (4.1%) 108 (11.9%) 101 (11.1%) 7 (0.8%) 
      ≥11 mm  16 (1.8%) 88 (9.7%) 168 (18.5%) 272 (29.0%) 202 (22.2%) 70 (7.7%) 
pTx  67 (7.4%) 107 (11.8%) 83 (9.1%) 257 (28.3%) 232 (25.6%) 25 (2.8%) 
     1-10mm  36 (4.0%) 32 (3.5%) 22 (2.4%) 90 (9.9%) 85 (9.4%) 5 (0.6%) 
   ≥11 mm  31 (3.4%) 75 (8.3%) 61 (6.7%) 167 (18.4%) 147(16.2%) 20 (2.2%) 
n (%) 233 (25.7%) 321 (35.4%) 354 (39.0%) 908 (100%) 805 (88.7%) 103 (11.3%) 
Table 6. Tumour size, lymph nodes and distant metastases in children and adolescents with 
post-Chernobyl PTC according to AJCC/UICC TNM. 7th edition 
According to our data, 22.6% of our patients with post-Chernobyl PTC were treated in stage 
pT3N1b and nearly all cases with associated distant metastases belonged to this group. 
4.4 Comparison of sporadic PTC, PTC as second primary cancer and  
post-chernobyl PTC 
We analyzed pathologic peculiarities, associated with local carcinoma spread (Table 7) and 
metastases in lymph nodes (Table 8). 
Thus, high risk of extrathyroidal extension in patients with sporadic PTC is associated with 
several morphological peculiarities: 
1. Tumour size≥11 mm 
2. Subcapsular localization 
3. Diffuse sclerosing variant (classical) 
4. Massive intratumoural fibrosis (central scarring) 
5. Blood or/and lymph vessel involvement 
In PTC as second primary malignancy, only lymph vessel involvement seems to be a 
predictor of the risk for extrathyroidal extension (however, we must bear in mind the small 
number of patients in this group). On the other hand, for post-Chernobyl PTC, 
extrathyroidal extension is correlated to many features: 
1. Tumour size≥11 mm 
2. Subcapsular or isthmus localization 
3. Predominance of follicular structures 
4. Diffuse sclerosing variant and monofocal papillary carcinoma with diffuse sclerosing 
involvement of the thyroid gland (DSV-like) as well 
5. Infiltrative growth and/or diffuse involvement (DSV and DSV-like) 
6. Massive intratumoural fibrosis (central scarring) 
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Pathology sporadic PTC second primary PTC post-Chernobyl PTC 
pT-stage 
P value
pT-stage 
P value
pT-stage 
P value T1&T2 
(n=54) 
T3&T4 
(n=60) 
T1&T2 
(n=6) 
T3&T4 
(n=17) 
T1&T2 
(n=271)
T3&T4 
(n=380) 
Tumour size:          
≥11 mm 22 
(40.7%)
43 
(71.7%)
0.0012 3 (50.0%) 6 (35.3%) NS 92 
(33.9%)
272 
(71.6%) 
< 
0.0001 
Localization 
(dominant): 
         
Subcapsular 11 
(20.4%)
31 
(51.7%)
0.0008 3 (50.0%) 11 
(64.7%)
NS 74 
(27.3%)
270 
(71.1%) 
< 
0.0001 
Inside lobe 40 
(74.1%)
21 
(35.0%)
< 
0.0001 
3 (50.0%) 4 (23.4%) NS 188 
(69.4%)
82 
(21.5%) 
< 
0.0001 
Isthmus 3  
(5.5%) 
8 (13.3%) NS 0 2 (11.8%) NS 9  
(3.3%) 
28  
(7.4%) 
0.0380 
Tumour 
histology, 
dominate 
architecture: 
         
Papillary 25 
(46.3%)
20 
(33.3%)
NS 3 (50.0%) 6 (35.3%) NS 109 
(40.2%)
102 
(26.8%) 
0.0004 
Follicular 22 
(40.7%)
25 
(41.7%)
NS 3 (50.0%) 8 (47.0%) NS 121 
(44.7%)
204 
(53.7%) 
0.0260 
Solid 7 (13.0%) 15 
(25.0%)
NS 0 3 (17.7%) NS 41 
(15.1%)
74 
(19.5%) 
NS 
Histological 
types:  
  
Classical 27 
(50.0%)
20 
(33.3%)
NS 3 (50.0%) 5 (29.2%) NS 110 
(40.6%)
127 
(33.4%) 
NS 
Follicular 13 
(24.1%)
12 
(20.0%)
NS 3 (50.0%) 2 (11.8%) NS 91 
(33.6%)
127 
(33.4%) 
NS 
Diffuse 
sclerosing(DSV) 
0 9 (15.0%) 0.0030 0 2 (11.8%) NS 0 18 (4.7%) < 
0.0001 
Monofocal with 
diffuse 
sclerosing 
involvement 
(DSV-like) 
3   (5.5%) 2   (3.4%) NS 0 2 (11.8%) NS 5     
(1.8%) 
20 
 (5.3%) 
0.0365 
Tall cell 6 (11.1%) 9 (15.0%) NS 0 3 (17.7%) NS 30 
(11.1%)
27 
(7.1%) 
NS 
Solid 5   (9.3%) 8 (13.3%) NS 0 3 (17.7%) NS 33 
(12.2%)
59 
(15.5%) 
NS 
Oncocytic 0 0 NS 0 0 2     
(0.7%)
1    
(0.3%) 
NS 
Clear cell 0 0 NS 0 0 0 1    
(0.3%) 
NS 
Pathological 
specifications: 
         
Infiltrative 
growth 
37 
(68.5%)
49 
(81.7%)
NS 3 (50.0%) 13 
(76.5%)
NS 197 
(72.7%)
337 
(88.7%) 
< 
0.0001 
circumscribed/ 
encapsulated 
growth 
14 
(26.0%)
0  < 
0.0001 
 
3 (50.0%) 0 0.0113 69 
(25.5%)
5  
(1.3%) 
< 
0.0001 
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Pathology sporadic PTC second primary PTC post-Chernobyl PTC 
pT-stage 
P value
pT-stage 
P value
pT-stage 
P value T1&T2 
(n=54) 
T3&T4 
(n=60) 
T1&T2 
(n=6) 
T3&T4 
(n=17) 
T1&T2 
(n=271)
T3&T4 
(n=380) 
diffuse 
involvement 
(DSV and DSV-
like) 
3  
(5.5%) 
11 
(18.3%)
NS 0 4 (23.5%) NS 5  
(1.8%) 
38 
(10.0%) 
< 
0.0001 
Fibrosis          
focal 
intratumoural 
fibrosis 
34 
(63.0%)
27 
(45.0%)
NS 1 (16.7%) 10 
(58.8%)
NS 152 
(56.1%)
145 
(38.2%) 
< 
0.0001 
septal 10 
(18.5%)
3  
(5.0%) 
0.0365 2 (33.3%) 4 (23.5%) NS 58 
(21.4%)
54 
(14.2%) 
0.0203 
massive (central 
scarring) 
9 (16.7%) 29 
(48.3%)
0.0004 1 (16.7%) 3 (17.7%) NS 41 
(15.1%)
173 
(45.5%) 
< 
0.0001 
Blood vessel 
involvement 
5  
(9.3%) 
22 
(36.7%)
0.0008 2 (33.3%) 6 (35.3%) NS 22  
(8.1%) 
114  
(30.0%) 
< 
0.0001 
Lymph vessel 
involvement 
31 
(57.4%)
60 
(100%) 
< 
0.0001 
2 (33.3%) 16 
(94.1%) 
0.0078 169 
(62.4%)
359 
(94.5%) 
< 
0.0001 
Mononuclear 
infiltration 
         
nodular type 9 (16.7%) 15 
(25.0%)
NS 0 4 (23.5%) NS 22  
(8.1%) 
76 
(20.0%) 
< 
0.0001 
sparse 32 
(59.3%)
32 
(53.3%)
NS 5 (83.3%) 12 
(70.6%)
NS 213 
(78.6%)
268 
(70.5%) 
0.0223 
Autoimmune 
thyroiditis 
comorbidity 
12 
(22.2%)
10 
(16.7%)
NS 0 0  26   
(9.6%) 
23  
(6.1%) 
NS 
Table 7. The relationship between characteristics of the primary tumour and spread of 
sporadic, second-primary and post-Chernobyl PTC beyond the thyroid gland capsule  
(Note: N.S. – not significant) 
7. Blood or/and lymph vessel involvement 
8. Nodular type of mononuclear infiltration 
In our opinion, the most intriguing finding is the association between radiogenic PTC and a 
predominantly follicular architecture with extrathyroidal extension. It should be mentioned 
that tumours with pure follicular, papillary or solid pattern had no preponderance for local 
spread beyond the thyroid gland but carcinomas of mixed structure did (p<0.001). In 
addition, if any follicular or solid formation was identified in the post-Chernobyl PTCs, it 
was also commonly associated with extrathyroidal extension (p<0.001 if solid structures 
appeared and p=0.03 for whichever size of follicular pattern). These differences may be 
explained by the molecular features of PTC in children and adolescents, as well as by 
peculiarities of tumour growth in young individuals.  
High risk of metastases in regional lymph nodes in patients with sporadic PTC is associated 
with several morphological peculiarities: 
1. Largely subcapsular localization 
2. Diffuse sclerosing variant (classical) 
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Pathology 
sporadic PTC second-primary PTC post-Chernobyl PTC 
pN-stage 
P value
pN-stage 
P value
pN-stage 
P value N0 
(n=42) 
N1 
(n=108) 
N0 
(n=6) 
N1 
(n=17)
N0 
(n=233)
N1 
(n=675) 
Tumour size:          
≥11 mm 22 
(52.4%) 
70 
(64.8%) 
NS 4 
(66.7%)
5 
(29.4%)
NS 75 
(32.2%)
456 
(67.6%) 
< 0.0001 
Localization 
(dominant): 
         
Subcapsular 10 
(23.8%) 
44 
(40.7%) 
0.0008 3 
(50.0%)
11 
(64.7%)
NS 79 
(33.9%)
364 
(53.9%) 
< 0.0001 
Inside lobe 31 
(73.8%) 
52 
(48.1%) 
< 0.0001 3 
(50.0%)
4 
(23.4%)
NS 146 
(62.7%)
270 
(40.0%) 
< 0.0001 
Isthmus 1     
(2.4%) 
12 
(11.2%) 
NS 0 2 
(11.8%)
NS 8 
(3.4%) 
41  
(6.1%) 
0.0380 
Tumour 
histology/ 
dominate 
architecture: 
         
Papillary 9   
(21.4%) 
50 
(46.3%) 
NS 3 
(50.0%)
6 
(35.3%)
NS 52 
(22.3%)
240 
(35.5%) 
0.0004 
Follicular 24 
(57.2%) 
33 
(30.6%) 
NS 3 
(50.0%)
8 
(47.0%)
NS 137 
(58.8%)
307 
(45.5%) 
0.0260 
Solid 9   
(21.4%) 
25 
(23.1%) 
NS 0 3 
(17.7%)
NS 44 
(18.9%)
128 
(19.0%) 
NS 
Histological 
types:  
         
Classical 13 
(31.0%) 
48 
(44.4%) 
NS 3 
(50.0%)
5 
(29.2%)
NS 73 
(31.3%)
278 
(41.2%) 
NS 
Follicular 16 
(38.1%) 
15 
(13.9%) 
NS 3 
(50.0%)
2 
(11.8%)
NS 104 
(44.6%)
180 
(26.7%) 
NS 
Diffuse 
sclerosing 
(DSV) 
0 9 (8.3%) 0.0030 
 
0 2 
(11.8%)
NS 0 26 (3.9%) < 0.0001 
Monofocal 
with diffuse 
sclerosing 
involvement 
(DSV-like) 
1     
(2.4%) 
11 
(10.2%) 
NS 0 2 
(11.8%)
NS 3 (1.3%) 41  (6.1%) 0.0365 
Tall cell 7   
(16.7%) 
12 
(11.1%) 
NS 0 3 
(17.7%)
NS 14 
(6.0%) 
54  (8.0%) NS 
Solid 5   
(11.8%) 
13 
(12.1%) 
NS 0 3 
(17.7%)
NS 36 
(15.5%)
92 
(13.6%) 
NS 
Oncocytic 0 0 NS 0 0  2 (0.9%) 3 (0.4%) NS 
Clear cell 0 0 NS 0 0  1 (0.4%) 1 (0.1%) NS 
Morphological 
specifications: 
         
Infiltrative 
growth 
25 
(59.5%) 
86 
(79.6%) 
NS 3 
(50.0%)
13 
(76.5%)
NS 158 
(67.8%)
592 
(87.7%) 
< 0.0001 
circumscribed/
encapsulated 
growth 
16 
(38.1%) 
2  
(1.9%)  
< 0.0001
 
3 
(50.0%)
0 0.0113 72 
(30.9%)
16  
(2.4%) 
< 0.0001 
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Pathology 
sporadic PTC second-primary PTC post-Chernobyl PTC 
pN-stage 
P value
pN-stage 
P value
pN-stage 
P value N0 
(n=42) 
N1 
(n=108) 
N0 
(n=6) 
N1 
(n=17)
N0 
(n=233)
N1 
(n=675) 
Diffuse 
involvement 
(DSV and 
DSV-like) 
1     
(2.4%) 
20 
(18.5%) 
NS 0 4 
(23.5%)
NS 5  
(1.8%) 
67  
(9.9%) 
< 0.0001 
Fibrosis          
Focal 
Septal 
26 
(61.9%) 
5   
(11.9%) 
59 
(54.6%) 
14 
(13.0%) 
NS 
NS 
1 
(16.7%)
2 
(33.3%)
10 
(58.8%)
4 
(23.5%)
NS 
NS 
111 
(47.6%)
57 
(24.5%)
296 
(43.8%) 
96 
(14.2%) 
NS 
0.0005 
Massive 
(central 
scarring) 
11 
(26.3%) 
33 
(30.6%) 
NS 1 
(16.7%)
3 
(17.7%)
NS 45 
(19.7%)
269 
(39.9%) 
< 0.0001 
Blood vessels 
involvement 
3     
(7.1%) 
26 
(24.1%) 
0.0206 2 
(33.3%)
6 
(35.3%)
NS 26 
(11.2%)
146 
(21.6%) 
< 0.0001 
Lymph vessels 
involvement 
14 
(33.3%) 
106 
(98.1%) 
< 0.0001 2 (33.3) 16 (94.1) 0.0078 104 
(44.6) 
649 (96.2) < 0.0001 
Mononuclear 
infiltration 
         
Nodular type 1     
(2.4%) 
32  
(29.6%) 
< 0.0001 0 4 
(23.5%)
NS 15 
(6.4%) 
123 
(18.2%) 
< 0.0001 
Sparse 26 
(61.9%) 
48 
(44.4%) 
NS 5 
(83.3%)
12 
(70.6%)
NS 184 
(79.0%)
489 
(72.4%) 
0.0223 
Autoimmune 
thyroiditis 
comorbidity 
13 
(30.9%) 
25 
(23.1%) 
NS 0 0  18 
(7.7%) 
49 
(7.3%) 
NS 
Table 8. The relationship between tumour characteristics and nodal involvement of 
sporadic, second-primary and post-Chernobyl PTC (Note: N.S. – not significant) 
3. Blood or/and lymph vessel involvement 
4. Nodular type of mononuclear infiltration 
High risk of nodal disease in patients with PTC as second primary malignancy 
(“iatrogenic”) is associated with only morphological detail: lymph vessel involvement. As 
for post-Chernobyl PTC it has the same characteristics for N1 as in a case of extrathyroidal 
spread excluding predominance of follicular architecture: 
1. Tumour size≥11 mm 
2. Subcapsular or isthmus localization 
3. Predominance of papillary structures 
4. Diffuse sclerosing variant and monofocal PTC with diffuse sclerosing involvement of 
the thyroid gland (DSV-like) as well 
5. Infiltrative growth and/or diffuse involvement (DSV and DSV-like) 
6. Massive intratumoural fibrosis (central scarring) 
7. Blood or/and lymph vessel involvement 
8. Nodular type of mononuclear infiltration 
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Comparing morphological specifications which are rather important for nodal disease and 
extrathyroidal spread it should be noted that many features are intermixed. Association of the 
nodular type of productive inflammation with increased risk of expansion of metastases in 
lymph nodes (p<0.001) may have several explanations. First, cytokines and chemokines 
produced by mononuclear cells promote the survival of tumors, especially clones that 
developed as a result of activation of the RET proto-oncogene (e.g. mainly observed in the 
papillary phenotype). Variants of papillary carcinoma with remarkable ability for invasion of 
lymphatic vessels and metastatic dissemination can appear as a result of such clone selection 
(lymphogenous, intrathyroidal and regional). Secondly, extended antigen stimulation by 
autoimmune thyroiditis (Hashimoto thyroiditis) may lead to emergence of papillary 
carcinoma through activation of ERK-kinase in epithelial cells (Guarino V. et al., 2010).  
Tumour histoarchitectonics probably play an important role in pathological and clinical 
behaviour of thyroid cancer but our current knowledge does not always permit a full 
understanding of the observations we have made. For example, why is a high proportion of 
follicular structures associated with stage pT3? And why is a largely papillary pattern 
associated with an elevated risk of N1 disease? Additionally, why do carcinomas of “pure” 
architecture appear less aggressive than PTC with mixed patterns? 
5. Conclusion 
Early assessment of post-Chernobyl thyroid carcinoma and sporadic thyroid carcinomas 
indicated that irradiation does not discriminate between genders; the female-to-male ratio 
was significantly higher in Italy and France (2.5/1), compared to the ratio of patients from 
post-Chernobyl Belarus (1.6/1). The overwhelming majority of the post-Chernobyl thyroid 
malignancies were PTC compared to a relatively high percentage of follicular carcinomas 
that was found in Italy/France (15.2%). This disproportion could be more likely explained 
by direct radiation-induced double-strand DNA breaks which preferentially lead to 
deletions and rearrangements. This mechanism is a characteristic for PTC but not for 
follicular carcinomas (DeLellies R.A. & Williams E.D., 2004), therefore predominance of PTC 
is non-directly supported radiation as a source for thyroid malignancies.  
While comparing the pathology of malignant thyroid tumors of pediatric Belarusian 
patients with naturally-occurring thyroid carcinomas from patients from Italy and France it 
was identified that extrathyroidal extension and lymph node metastases were significantly 
more frequent in thyroid cancers in Belarus (49.1%, 64.6% respectively) compared to thyroid 
cancers in Italy/France, where it was 24.9% and 53.9%, respectively. It was hypothesized 
that these differences depend on the age at presentation: mean age at diagnosis in radiation-
induced cases was 11 years in children and 15 years in adolescents while naturally-occurring 
thyroid carcinomas were diagnosed after 14 years of age (Pacini F. et al., 1997). Our research 
group and others documented that patient age did not have any influence on the tumors’ 
ability to grow beyond the thyroid capsule and /or metastasize to lymph nodes or internal 
organs (Machens A. et al., 2010). Moreover, based on the rate of thyroid lymphocytic 
infiltration and circulating antithyroperoxidase antibody it was suggested that thyroid 
autoimmunity could be an additional consequence of the Chernobyl accident (Pacini F. et 
al., 1997). However, it is quite normal for us to see full-blown mononuclear infiltration in 
patients with sporadic PTC as well (autoimmune thyroiditis plays the leading role in the 
background pathology (n=38, 25.3%)).  
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It seems to be logical that sporadic PTC in children and adolescents from Belarus show few 
differences in comparison with the well-known clinical and morphological features of non-
radiation induced thyroid cancers in other countries. For example, the female to male ratio is 
the same as in the rest of the world (3.7:1 in our own material, 4:1 for all histological variants 
of carcinoma according to long-term USA statistical data (Hogan et al., 2009). The lymph 
node metastases (72%) are as widespread as extrathyroidal extension (32.7%). In other 
countries the frequency of lymphatic nodes’ involvement in children and adolescents 
appears to be also at a high level - from 40.7% in Canada up to 84.3% in Germany (Machens 
et al., 2010; O’Gorman et al., 2010). The data concerning extrathyroidal extent also varies 
considerably: from 9.6% in Russia up to 67.6% in South Korea (Koo J. et al., 2009, 
Romanchishen et al., 2008). 
There are other nontrivial differences. In the period between 1986 and 2008 there were 150 
sporadic papillary carcinoma patients and 42 cases of other malignant tumours composed of 
follicular cells—well differentiated carcinoma, no other specified (as it was defined by 
international group of pathologists (LiVolsi et al., 2011) who participated in Chernobyl 
tissue bank project), n=22, follicular thyroid carcinoma (FTC, n=4), collision carcinomas such 
as PTC and FTC (n=3), poorly differentiated carcinoma (4) and cribriform morular variant of 
PTC (n=9). This contradicts the worldwide data that put follicular carcinoma in much 
significant place after papillary carcinoma (its frequency varies from 6.1% in Russia up to 
10-11% in Great Britain, Canada and the USA) (Romanchishen A.F. et al., 2008; Harach H.R. 
& Williams E.D., 1995; O’Gorman C.S. et al., 2010; Hogan et al., 2009). Besides, in our 
research primary tumor size (mean 15.8±14.3 mm, median 12 mm) was smaller than in 
German (median 31 mm) and Canadian (mean 23±15 mm) children and adolescents 
(Machens A. et al., 2010; O’Gorman C.S. et al., 2010). Moreover, multifocal growth was 
observed rarely, though other reports indicate that childhood thyroid cancers are typically 
not multifocal (Grigsby P.W. et al., 2002; DeLellies, R.A. & Williams, 2004). Finally, though 
prior reports have indicated that PTC in children and adolescents is prone to relapse 
(Demidchik Y.E. et al., 2006; Grigsby P.W. et al., 2002; Naing S. et al., 2009), with one report 
indicating a recurrence rate of up to 34% (Grigsby P.W. et al., 2002), here we observed a 
recurrence in only one case.  
A notion prevails that radiogenic and sporadic papillary cancers do not differ in phenotype, 
but the distribution of variants of papillary carcinoma in both groups are a little different. 
For example, Ukrainian and Russian reports of post-Chernobyl cancer in children and 
adolescents indicate that the follicular (follicular-solid) variant occurs much more often than 
others types (Tronko M.D. et al., 1999; Williams E.D. et al., 2004). On the contrary, carcinoma 
of classical structure dominates in paediatric sporadic carcinomas (Harach H.R. & Williams 
E.D., 1995). Some researchers state that DSV appears in children and adolescents more often. 
However, as shown in tables 1, 3 and 5, regardless of the aetiology, the most frequent 
variant of carcinoma in children and adolescents in Belarus is the classical variant of 
papillary carcinoma.  
Patients who received treatment for Hodgkin's lymphoma comprised 40.1% of all thyroid 
cancers that occurred as second primary malignancies. Children fell ill at an average age of 
7. Such tumors appear in boys more often than in girls (6 boys and three girls in our own 
material). Moreover, in both cases of non-Hodgkins lymphoma, male patients were affected. 
As a result, gender proportion typical for the first cancer determined the ultimate 
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predominance of boys in the group of patients with second primary cancers. However, in 
the work of Acharya et al. (2003), out of 33 patients with confirmed history of therapeutic 
irradiation, 18 were diagnosed with Hodgkin's disease. Ten others had non-Hodgkin’s 
lymphoma and 3 had acute leukemia, but the gender proportion was 2.3:1 girls:boys. The 
exact age when the first malignant tumour grew is not given (the median is given – 12 years 
and interval – from 3.7 to 18.3 years) and in the quoted research thyroid cancer appeared in 
the interval from 6.2 to 30.1 years.  
Other features that indicate a difference between the variants of PTC of different aetiology 
are directly connected with the parameters of pathological aggressiveness. Ability to spread 
into surrounding tissues (pT3) is to a greater degree characteristic for second-primary 
carcinoma (73.9% of all observations). High frequency of autoimmune thyroiditis again 
brings up the question of what comes first: cancer in the background of a chronic 
inflammatory process or changes observed by the pathologist in surgical material that 
indicate a tumour-associated immunoreaction. It may also be theorized that long existing 
inflammatory responses with associated tissue renewal and repair leads to lower degrees of 
aggressiveness of thyroid carcinoma since it is connected to both upregulation of molecules 
of major histocompatibility complex (for example, HLA-Dr) or direct cytotoxic action of 
lymphocytes and macrophages on tumour cells (Guarino V. et al., 2010), with structural 
reorganization of thyroid gland tissue. Sclerosis, hyalinosis and mechanical compression of 
lymphatic vessels or compensatory-adaptive node of vascular walls as a response to local 
anoxia should have considerably impeded tumour cell embolism. Nevertheless, in our 
research autoimmune thyroiditis was identified in patients from both the sporadic and post-
Chernobyl carcinoma groups and did not influence the invasive or metastatic potential. 
Ultimately, tumour aetiology has no real impact on the clinical course and on the overall 
favourable prognosis of thyroid carcinoma, and the age of patients (children as compared to 
adolescents) is not essential for treatment planning or for disease outcome (Machens et al., 
2010). On the other hand, observations show that the exposure to irradiation potentially 
induces clinicopathological characteristics of high-grade thyroid carcinomas, e.g. potential 
for multifocal growth, lymphovascular invasion, extrathyroidal spread, regional and distant 
metastasis, or recurrences (Naing et al., 2009). With the help of various statistical methods 
our own research discovered some characteristics which indicate clinical courses of 
papillary carcinomas in patients with the history of irradiation somewhat differ from the 
one of sporadic carcinomas, but the prognostic significance of this fact is not yet clear in 
spite of our large cohort of post-Chernobyl cancers. We believe that a more extended 
observation period and addition of new cases of sporadic and second-primary papillary 
carcinomas to the cohorts described here will give the possibility to define more precisely 
the role that aetiology plays for prognosis and treatment planning in children and 
adolescents.  
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